Proteonomix, Inc. Announces Its Clinical Trial of UMK-121 in
Patients with End Stage Liver Disease Has Been Listed on
ClinicalTrials.gov
PARAMUS, N.J., Oct. 23, 2012 /PRNewswire/ -- PROTEONOMIX,
INC. (OTCBB: PROT), a biotechnology company focused on developing
therapeutics based upon the use of human cells and their
derivatives, announced today that the Company's clinical trial of
UMK-121 in patients with End Stage Liver Disease has been listed on
ClinicalTrials.gov and provided with an Identifier code of
NCT01711073.
The listing on ClinicalTrials.gov under regulation FDAAA
801 provides information for families, patients, clinicians,
and researchers regarding the trial and its status. We thank the
University of Medicine & Dentistry of New
Jersey for providing the IRB, a key factor for registration
on ClinicalTrials.gov.
Michael Cohen, President of the
Company, stated: "We are continuing to progress with our advances
and with our target to initiate the clinical trial of UMK-121 in
patients with End Stage Liver Disease." The Company
will work together with the University and the principal
investigators to initiate the clinical study. "The listing of the
trial on ClinicalTrials.gov provides patients and their families
the opportunity to review the study and evaluate its progress."
About ClinicalTrials.gov
ClinicalTrials.gov is a Web-based resource that provides
patients, their family members, health care professionals,
researchers, and the public with easy access to information on
publicly and privately supported clinical studies on a wide range
of diseases and conditions. The Web site is maintained by the
National Library of Medicine (NLM) at the National Institutes of
Health (NIH). Information on ClinicalTrials.gov is provided and
updated by the sponsor or principal investigator of the clinical
study. Studies are generally submitted to the Web site (that is,
registered) when they begin, and the information on the site is
updated throughout the study. In some cases, results of the study
are submitted after the study ends. This Web site and database of
clinical studies is commonly referred to as a "registry" and
"results database." For more information on ClinicalTrials.gov
visit the site.
About Proteonomix, Inc.
Proteonomix is a biotechnology company focused on developing
therapeutics based upon the use of human cells and their
derivatives. The Proteonomix family of companies includes
Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a
wholly owned subsidiary that has developed an anti-aging line of
skin care products. StromaCel develops therapeutic modalities for
the treatment of cardiovascular disease and for treatment of
patients who have suffered post-myocardial infarction. Proteonomix
Regenerative Translational Medicine Institute, Inc. (PRTMI) intends
to focus on the translation of promising research in stem cell
biology and cellular therapy to clinical applications of
regenerative medicine. Additional information is available at
www.proteonomix.com and www.proteoderm.com.
Forward-looking statements:
Certain statements contained herein are "forward-looking
statements" (as defined in the Private Securities Litigation Reform
Act of 1995). Proteonomix, Inc. cautions that statements made in
this press release constitute forward-looking statements and makes
no guarantee of future performance. Actual results or developments
may differ materially from projections. Forward-looking statements
are based on estimates and opinions of management at the time
statements are made.
SOURCE Proteonomix, Inc.